Standard-dose intravenous tenecteplase

Phase 3Protein / enzyme

TThe George Institute

Standard-dose intravenous tenecteplase is one of 41 therapeutic programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

StrokeRecruiting

StrokePhase 3

Recruiting

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Standard-dose intravenous tenecteplase

TThe George Institute

Phase 3

1 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Zantac 150

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2034

Phase 3Recruiting

Stroke

NCT06352632

Clinical

Trials by Indication[1]

Stroke1 trial

A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL)

Recruiting·TThe George Institute·Phase 3·NCT06352632·20,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard-dose intravenous tenecteplase. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard-dose intravenous tenecteplase. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — The George Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme
Highest Phase: Phase 3[1]
Company: TThe George Institute

Standard-dose intravenous tenecteplase

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2034

Trials by Indication[1]

Stroke1 trial

References

Drug Info

Quick Facts

Related News